Total
0
Shares
Proteomics International (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics International Laboratories (PIQ) engages Biotem to manufacture its test kits
  • The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test
  • The agreement spans over three years, with the option to extend for additional periods of one year
  • Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST

Proteomics International Laboratories (PIQ) has contracted a French immunoassay specialist to manufacture its test kits.

The company, Biotem, has been contracted to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease, using a ‘fingerprint’ of protein biomarkers in the blood.

The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test.

“Now, by contracting these specialist manufacturers we are building our production capacity to meet our anticipated demand for the test in the Northern Hemisphere and worldwide,” said Proteomics’ managing director, Dr Richard Lipscombe.

The agreement spans over three years, with the option to extend for additional periods of one year. During this time, Biotem will manufacture PromarkerD test kits on a fee-for-service basis.

The announcement follows reagent producer, Abcam being contracted for a world first predictive test for diabetic kidney disease.

“The engagement of global manufacturing partners will help accelerate the worldwide roll-out of PromarkerD, as well as the commercialisation of our pipeline of other diagnostics under development,” said Dr Lipscombe.

Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST.

PIQ by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.